Egalet Corporation, a fully integrated specialty pharmaceutical company, has reached an agreement with Purdue Pharma L.P. as it relates to alleged patent infringements against Egalet and product licensor Acura Pharmaceuticals, Inc. for Oxaydo (oxycodone HCl, USP) tablets CII.

In April 2015 and April 2016 Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. filed patent infringement lawsuits against Egalet for Oxaydo alleging the product infringes Purdue's US Patent No. 8,389,007 and US Patent No. 9,308,171, respectively. Purdue has agreed to dismiss the complaints and both parties have agreed not to pursue any further action on Oxaydo, an immediate-release opioid product. There are no financial obligations to either party.

"This agreement allows us to market Oxaydo without the risk of future litigation with Purdue," said Bob Radie, president and chief executive officer at Egalet. "Having reached a mutually agreeable outcome on this action, we can focus on continuing to bring Oxaydo to health care professionals in their efforts to help individuals manage their pain while discouraging potential nasal abuse."

Oxaydo is an immediate-release oral formulation of oxycodone HCl indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. It is the first and only approved immediate-release oxycodone product designed to discourage intranasal abuse.

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: Oxaydo (oxycodone HCI, USP) tablets for oral use only –CII and Sprix (ketorolac tromethamine) nasal spray.